Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?

被引:11
|
作者
Britt, Nicholas S. [1 ,7 ]
Ritchie, David J. [1 ,2 ]
Kollef, Marin H. [3 ]
Burnham, Carey-Ann D. [4 ]
Durkin, Michael J. [5 ]
Hampton, Nicholas B. [6 ]
Micek, Scott T. [1 ,2 ]
机构
[1] Barnes Jewish Hosp, Dept Pharm, St Louis, MO 63110 USA
[2] St Louis Coll Pharm, Dept Pharm Practice, St Louis, MO USA
[3] Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Pathol & Immunol, Pediat & Mol Microbiol, St Louis, MO USA
[5] Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63110 USA
[6] BJC HealthCare, Ctr Clin Excellence, St Louis, MO USA
[7] Univ Kansas, Sch Pharm, Dept Pharm Practice, 3901 Rainbow Blvd,Mailstop 4047, Kansas City, KS 66160 USA
基金
美国国家卫生研究院;
关键词
Carbapenem resistance; Multidrug resistance; Sepsis; Carbapenem-resistant Enterobacteriaceae; Pseudomonas aeruginosa; ENTEROBACTER-CLOACAE; PSEUDOMONAS-AERUGINOSA; BETA-LACTAMASES; BRUKER BIOTYPER; UNITED-STATES; IDENTIFICATION; METAANALYSIS; MORTALITY;
D O I
10.1016/j.ajic.2018.03.013
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Infections caused by carbapenem-resistant gram-negative bacilli are an emerging public health threat. However, there is a paucity of data examining comparative incidence rates, risk factors, and outcomes in this population. Methods: This single-center retrospective cohort study was conducted at an urban tertiary-care academic medical center. We included patients admitted from 2012 to 2015 who met the following criteria: i) age >= 18 years; and ii) culture positive for carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemresistant non-Enterobacteriaceae (CRNE) from any site. Exclusion criteria were: i) < 2 systemic inflammatory response criteria; ii) cystic fibrosis; and iii) no targeted treatment. We evaluated hospital survival by Cox regression and year-by-year differences in the distribution of cases by the Cochran-Armitage test. Results: 448 patients were analyzed (CRE, n = 111 [24.8%]; CRNE, n = 337 [75.2%]). CRE sepsis cases increased significantly over the study period (P <.001), driven primarily by increasing incidence of Enterobacter spp. infection (P =.004). No difference was observed in hospital survival between patients with CRE versus CRNE sepsis (hazard ratio [HR], 1.29; 95% confidence interval [CI], 0.83-2.02; P =.285), even after adjusting for confounding factors (adjusted HR, 1.08; 95% CI, 0.62-1.87; P =.799). Conclusions: Clinical outcomes did not differ between patients with CRE versus CRNE sepsis. Dramatic increases in CRE, particularly Enterobacter spp., appear to be causing a shift in the burden of clinically significant carbapenem-resistant gram-negative infection. (C) 2018 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1092 / 1096
页数:5
相关论文
共 50 条
  • [41] Infective endocarditis by carbapenem-resistant Gram-negative bacteria - a systematic review
    Pitsikakis, Konstantinos
    Skandalakis, Michail
    Fragkiadakis, Konstantinos
    Baliou, Stella
    Ioannou, Petros
    GERMS, 2024, 14 (02): : 149 - 161
  • [42] Characterization of carbapenem-resistant Gram-negative bacteria from Tamil Nadu
    Nachimuthu, Ramesh
    Subramani, Ramkumar
    Maray, Suresh
    Gothandam, K. M.
    Sivamangala, Karthikeyan
    Manohar, Prasanth
    Bozdogan, Bulent
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (05) : 371 - 374
  • [43] The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
    Teena Chopra
    Infectious Diseases and Therapy, 2021, 10 : 633 - 635
  • [44] Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia
    Shields, Ryan K.
    Zhou, Yun
    Kanakamedala, Hemanth
    Cai, Bin
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [45] Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms
    Kois, Abigail K.
    Nicolau, David P.
    Kuti, Joseph L.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2020, 33 (06) : 482 - 494
  • [46] Early identification and optimal management of carbapenem-resistant Gram-negative infection
    Bedos, J. P.
    Daikos, G.
    Dodgson, A. R.
    Pan, A.
    Petrosillo, N.
    Seifert, H.
    Vila, J.
    Ferrer, R.
    Wilson, P.
    JOURNAL OF HOSPITAL INFECTION, 2021, 108 : 158 - 167
  • [47] Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia
    Ryan K. Shields
    Yun Zhou
    Hemanth Kanakamedala
    Bin Cai
    BMC Infectious Diseases, 21
  • [48] Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017
    Babiker, Ahmed
    Clarke, Lloyd G.
    Saul, Melissa
    Gealey, Julie A.
    Clancy, Cornelius J.
    Nguyen, M. Hong
    Shields, Ryan K.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E4521 - E4530
  • [49] Emergence of Carbapenem-Resistant Gram-Negative Isolates in Hospital Settings in Djibouti
    Ragueh, Ayan Ali
    Aboubaker, Mohamed Houmed
    Mohamed, Sitani Idriss
    Rolain, Jean-Marc
    Diene, Seydina M.
    ANTIBIOTICS-BASEL, 2023, 12 (07):
  • [50] The global threat of carbapenem-resistant gram-negative bacteria, volume II
    Daoud, Ziad
    Dropa, Milena
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13